HYTERA
17.3.2022 08:37:06 CET | Business Wire | Press release
Technology underpins the successful running of all kinds of mega events. Audiences these days are constantly amazed by the top-notch technologies adopted by the Beijing 2022 Winter Olympics and Paralympic Winter Games. Among them, the professional mobile radios (PMR), which support critical communications of the world-class event, have earned wide attention from the public.
As one of the key communication solution suppliers of Beijing 2022 Winter Olympic and Paralympic Winter Games, Hytera provided a certain amount of TETRA devices, PMR-LTE convergent solutions and command & control systems to the security officers and rescue teams during the races. Hytera’s communication technologies also played a major role in the execution of COVID-19 prevention in the Olympic Village.
In fact, besides the global mega sport events, Hytera’s products and solutions are also chosen by industry clients across public safety, transportation, manufacturing, oil and gas as well as the retail and hospitality industries.
Innovation Is in Hytera’s DNA
With continuous investment in technology innovation, Hytera is committed to promoting open communication standards from narrowband to broadband, including TETRA, DMR, PDT and LTE with independent intellectual property rights, which makes it a leading provider of professional communication solutions.
Hytera recently added the H Series to its DMR product portfolios. The new series is built from the ground up on an entirely new technology platform. It is the first of its kind in the industry when it comes to functionality, user experience, and ruggedness, providing efficient and reliable communications to users in security, education industry and customer service roles as well as those working in severe working conditions.
Global Recognition and Partnership Achieved by Hytera
To meet the growing needs of business and critical communication users, Hytera innovatively developed a variety of products and technology solutions. Among them, there are DMR terminals, TETRA terminals, PoC Radios, multimode advanced radios, body worn cameras, command & dispatch and emergency response software that have contributed to the success of users working in the vertical industries, such as public safety, energy, transportation, utility, commercial and operator markets. With audio, visual and data capabilities, Hytera has provided faster, safer, and more versatile connectivity options.
Hytera has showcased its technological strength and achieved global recognition and partnerships. The International Critical Communications Awards (ICAA) awarded Hytera the “Best New LTE or Hybrid Device” for its LTE & TETRA convergent device PTC760, as well as the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC solution for Turkey Electricity Company.
Global partnerships have also validated Hytera’s competence. Hytera played a role in the 2021 FIFA Arab Cup and the 2018 FIFA World Cup with its local partners. Hytera also worked with the security department in Tajikistan during the SCO Summit 2021.
Supporting Communities under Global Challenges
While succeeding in landing international business partnerships, Hytera has also contributed its capacities to tackle global challenges.
To deal with the outbreak of the COVID-19 pandemic, Hytera has actively contributed its capabilities to improve disease prevention. Hytera’s two way radios and pandemic prevention solutions provided fast and reliable non-contact communication to the workers from hospitals, enterprises and security departments around the world to fight against the virus.
As a key player in the critical communications industry, Hytera, empowered by top-performing technologies, will continue to support industrial users, and ensure safer and stronger communication networks worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006155/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
